Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Cellular Dynamics Announces Presentations at the SOT Annual Meeting

Published: Saturday, March 22, 2014
Last Updated: Friday, March 21, 2014
Bookmark and Share
Highlighting use of iPSC-derived human cells for environmental toxicology and drug toxicity testing.

Cellular Dynamics International, Inc. has announced scientific presentations at the Society of Toxicology’s 53nd Annual Meeting (SOT), March 23 to 27 in Phoenix.

Key points:
• Multiple presentations, symposia and workshops demonstrate the expanding utility of CDI’s iCell® products on toxicology assay development.
• Several presentations describe research in the area of environmental toxicology; this highlights the expanding utility of CDI’s iCell and MyCell® Products outside of their traditional use in pharmaceutical toxicity testing and basic human biological research.

Quote:
Chris Parker, chief commercial officer of CDI said, “Our pharmaceutical and life science customers continue to find new ways to apply our iCell and MyCell Products to their drug development and research priorities. What is especially exciting for us is the increasing use of our cells outside of the life sciences. Several presenters at this year’s SOT meeting describe environmental toxicology applications for our cells. Along with our recently announced collaboration with Nestlé, who are using our cells for nutritional research, the application of our cells in multiple scientific disciplines validates CDI’s scientific and commercial mission.”

Environmental Toxicology Presentations:
“Induced Pluripotent Stem Cell-derived Neurons as a Human Model for Testing Environmentally-induced Developmental Neurotoxicity,” presented by IL Druwe, US EPA, within the “Induced Human Pluripotent Stem Cells and Their Differentiated Progeny Cells: Implementation in Toxicity Testing” symposium, March 24, 9:15 am - 12:00 p.m.

“Phenotypic In Vitro Assessment of Compound Effects on Cardiomyocyte Physiology Using Human iPSC-derived Cardiomyocytes,” exhibitor-hosted session presented by CDI on NIEHS/NIH and pharmaceutical toxicity testing data, March 25, 1:30 - 2:30 pm.

“In Vitro Assessment of Cardiotoxicity Hazard of Environmental Compounds Using Fast Fluorescence Imaging of Beating iPSC-derived Cardiomyocytes,” poster presented by O Sirenko on NIEHS/NIH data, March 26, 9:00 am - 12:30 pm, Abstract 1616g.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

The Hamner Institutes and Cellular Dynamics Collaborate
The parties will develop predictive in vitro screening assays for chemical, environmental and pharmaceutical toxicology assessments.
Monday, December 09, 2013
GE Healthcare and Cellular Dynamics International Agree to Sublicense for Cellular Assay Patents
Companies have announced that GE Healthcare has licensed CDI to develop, manufacture and sell cellular assays and models derived from iPS cells for use in drug discovery and toxicity screening.
Wednesday, December 19, 2012
Cellular Dynamics International and Roche Transition Early Access
Collaboration into a standard supply agreement ahead of schedule.
Saturday, March 26, 2011
CDI, ACEA and Roche Cooperate to Evaluate iCell Cardiomyocytes on the xCELLigence System
The partnership will bring early and accurate prediction of potential cardiotoxic side effects to the drug discovery process.
Tuesday, September 21, 2010
Cellular Dynamics Partners with iPS Academia Japan to In-License Seminal iPS Cell Patent Portfolio
Companies announce a nonexclusive licensing agreement for the seminal iPSC patent portfolio arising out of the work of Dr. Shinya Yamanaka.
Monday, May 10, 2010
Cellular Dynamics Raises $40.6 MM to Revolutionize Pharma Drug Research
The financing enables the company to increase production capacity for its iCell™ Cardiomyocytes and to launch additional human tissue cell products.
Thursday, April 29, 2010
CDI’s iCell™ Cardiomyocytes Named to MIT Technology Review’s Annual 10 Emerging Technologies List
iCell Cardiomyocytes are first human IPSC-derived cell type launched for high throughput drug discovery and toxicity testing.
Friday, April 23, 2010
Cellular Dynamics International In-Licenses Key Patent Portfolio for Using Stem Cell-Derived Cells in Drug Testing
Greater than 90 percent cell type purification enabled through exclusively licensed technology.
Friday, July 17, 2009
Cellular Dynamics International and Roche Expand Existing Cardiotoxicity Screening Agreement
The two-year collaboration aims to enhance drug safety testing in order to bring promising therapies to patients.
Thursday, July 02, 2009
Cellular Dynamics International Licenses Key Patent Portfolio Surrounding Cardiovascular Progenitor Cells
The exclusive license covers differentiation of stem cells into all cell types of the human heart.
Wednesday, June 03, 2009
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Alzheimer’s Protein Serves as Natural Antibiotic
Alzheimer's-associated amyloid plaques may be part of natural process to trap microbes, findings suggest new therapeutic strategies.
Vitamin A May Help Improve Pancreatic Cancer Chemotherapy
The addition of high doses of a form of vitamin A could help make chemotherapy more successful in treating pancreatic cancer, according to an early study by Queen Mary University of London (QMUL).
Breakthrough Approach to Breast Cancer Treatment
Scripps scientists have designed a drug candidate that decreases growth of breast cancer cells.
Non-Toxic Approach to Treating Variety of Cancers
A team of researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine recently discovered a novel, non-toxic approach to treating a wide variety of cancers.
Making Injectable Medicine Safer
Researchers remove excess additives from drugs, which could reduce the odds of serious allergic reactions and other side effects.
An Old-New Weapon Against Emerging Chikungunya Virus
Researchers utilize existing drugs to interfere with host factors required for replication of Chikungunya virus.
Brazilian Zika Virus Strain Causes Birth Defects in Experimental Models
First direct experimental proof of causal effect, researchers say.
'Kidney on a Chip' Facilitates Safer Drug Dosing
University of Michigan researchers have used a "kidney on a chip" device to mimic the flow of medication through human kidneys and measure its effect on kidney cells.
Ketamine Metabolism Lifts Depression
NIH-funded team finds rapid-acting, non-addicting agent in mouse study.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!